The clinical use of TNF-α inhibitors in the treatment of obstructive lung diseases such as asthma and chronic obstructive pulmonary disease is controversial and has been reported to be associated with potential adverse side effects. This evidence concerns the gene TNF and chronic obstructive pulmonary disease.